ClinicalTrials.gg
Active, not recruitingNCT06666855Updated May 15, 2026

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

A Phase 3 interventional study of DE-117B Eye Drops and Latanoprost in Open Angle Glaucoma and Ocular Hypertension, sponsored by Santen Pharmaceutical Co., Ltd.. Active, not recruiting at 24 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Santen Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. — 1 open to participants now, 2 under way, 1 of them phase 3. Glaucoma, Open-Angle · Santen Pharmaceutical Co., Ltd..

Enrollment
7th of 31
345 · median 165
Started
2024
the only one that year
Phase 3
17 of 37
none open now
Registered
36th of 37
by date

Among the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., this one is the 7th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2024, is one of 17 in phase 3, and was the 36th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study.

Subjects diagnosed with POAG (Primary Open Angle Glaucoma) or OHT (Ocular Hypertension) who meet eligibility criteria will washout of their current IOP lowering medication(s), if any.

The study will investigate plasma pharmacokinetics of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension.

It will investigate the safety of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension.

There will be a bridging cohort and extension follow-up phase

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with primary open angle glaucoma or ocular hypertension in both eyes.
  • Corrected visual acuity ≥0.2 in both eyes.
  • Anterior chamber angle grade ≥2 (Shaffer scale) in both eyes.
  • Central corneal thickness ≥480 μm to ≤600 μm in both eyes.
  • At completion of the phase, IOP ≥22 mmHg in at least one eye and ≤34 mmHg in both eyes at all measurement time points.

Exclusion criteria

Exclusion Criteria:

  • Consider visual field disorder at risk for progression during the study based on the current clinical examination result.
  • Severe visual field disorder (e.g., mean deviation lower than -12 dB, as assessed by Humphrey field analyzer).
  • Any corneal abnormality or other condition potentially interfering with reliable applanation tonometry.
  • History of iritis or uveitis.
  • Presence of any active external ocular disease, inflammation, or infection of the eye or eyelids.
  • History of macular oedema, retinal detachment, or diabetic retinopathy, or current retinal disease at risk for progression during the study.
  • History of refractive keratotomy.
  • History of invasive surgery for glaucoma (including laser therapy).
  • Anterior segment or intraocular surgery (other than glaucoma) within 90 days prior to start of washout phase.
  • History of severe eye injury.
  • History of allergy to agents that were to be used during the study (e.g., benzalkonium chloride, instillation anesthetics, fluorescein, latanoprost eye drops).
  • Intended use of prohibited concomitant medications or therapies during the study.
  • Required use of contact lenses from 1 week before treatment phase initiation and during the study.
  • Pseudophakic eye, aphakic eye.
  • Current participation in another clinical study, or participation and treatment with study medication within 90 days before the start of the phase.
  • Females who are pregnant, nursing, or potentially pregnant (e.g., positive pregnancy test), planning a pregnancy during the study, or unable to use appropriate during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
345 participants (actual)

Study arms

  • Experimental
    DE-117B Eye Drops

    0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for 4 weeks, followed by 0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for an extension follow-up phase of 12 months.

    Drug: DE-117B Eye Drops

  • Active comparator
    Latanoprost Eye Drops

    0.005% Latanoprost Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for 4 weeks, followed by 0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes for an extension follow-up phase of 12 months.

    Drug: Latanoprost

Interventions

  • DrugDE-117B Eye Drops

    Investigational Product: 0.002% DE-117B Eye Drops

  • Active Control: 0.005% Latanoprost Eye Drops

06

What researchers measure

Primary outcomes

  1. Intraocular Pressure (IOP) at Week 4

    Change from Baseline in Mean Diurnal IOP at Week 4

    Time frame: Week 4

Secondary outcomes

  1. Percent Change in Intraocular Pressure (IOP)

    Percent Change from Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 4

    Time frame: Week 4

  2. Change and Percent Change in Intraocular Pressure (IOP)

    Change and Percent Change from Baseline in Mean Diurnal IOP at each post baseline visit except week 4.

    Time frame: Post baseline Visits except Week 4

  3. Change and Percent Change from baseline in Intraocular Pressure (IOP)

    Change and Percent Change from baseline in IOP at each IOP assessment time point at each post baseline visit.

    Time frame: Assessment time point at each post baseline visit.

  4. Percentage of Responders

    Percentage of Responders (percent reduction from baseline in Mean Diurnal IOP: ≥20%, ≥25%, ≥30%) at each post baseline visit.

    Time frame: Each Post Baseline Visit.

07

Study locations

24 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Aug 2026, 21 months after the start.

Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 21 months is below that.

Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Oct 31, 2024
StartActual
Nov 28, 2024
Primary completionEst.
Aug 31, 2026
CompletionEst.
Aug 31, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06666855
Responsible party
Sponsor
First posted
Oct 31, 2024
Start date
Nov 28, 2024
Primary completion
Aug 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
May 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion